The Role of Clinical Proteomics, Lipidomics and Genomics in the diagnosis of Alzheimer's Disease

Research output: Contribution to conferenceAbstract

Abstract


The early diagnosis of Alzheimer’s disease (AD) has become important to the reversal and treatment of neurodegeneration that may be relevant to premature brain aging that is associated with chronic disease progression. Clinical proteomics allows the detection of various proteins in fluids such as the urine, plasma and cerebrospinal fluid for the diagnosis of AD. Interests in lipidomics has accelerated with plasma testing for various lipid biomarkers that may with clinical proteomics provide a more reproducible diagnosis. The combination of proteomics with lipidomics may decrease the biological variability between studies and provide reproducible results that detect a community’s susceptibility to AD (Ref1). The diagnosis of chronic disease associated with AD that now involves genomics may provide increased sensitivity to avoid inadvertent errors related to plasma versus cerebrospinal fluid testing by proteomics and lipidomics that identify new disease biomarkers in body fluids, cells and tissues. The diagnosis of AD by various plasma biomarkers with clinical proteomics may now require the involvement of lipidomics and genomics to provide interpretation of proteomic results from various laboratories around the world. Technological advances allow novel biomarkers to be identified for the diagnosis of neurodisorders but novel patents may not be relevant to diagnostic discovery with relevance to autonomous disease that involves magnesium and its association with various chronic diseases (Ref2). Ref1. The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer’s Disease. Proteomes, 2016. ONLINE Ref2. Magnesium Therapy Prevents Senescence with the Reversal of Diabetes and Alzheimer’s Disease. Health, 2016.ONLINE
Original languageEnglish
Publication statusPublished - 7 Sep 2016
Event2nd Neurological Disorders Summit - The Double Tree by Hilton Baltimore - BWI Airport Hotel, Baltimore, United States
Duration: 7 Sep 20169 Sep 2016
https://neurodisordersconference.com/neurology-2016/

Conference

Conference2nd Neurological Disorders Summit
Abbreviated titleNDS 2016
CountryUnited States
CityBaltimore
Period7/09/169/09/16
Other2nd Neurological Disorders Summit (NDS-2016) will provide a dedicated platform to share cutting-edge scientific findings, medical practices and caregiver initiatives related to various Neurological Disorders. The multidisciplinary meeting will bring together the scientific community - principal investigators, scientists, researchers, health professionals, analysts, clinicians, policy makers, industry experts, the well-established and the budding entrepreneurs to create a worldwide dialogue on various aspects and challenges of devastating neurological conditions.
NDS-2016 will engage global audience for the exchange of ideas and perspectives for better understanding of origin, development, clinical and translation science to deliver potential cure for neurological diseases. This international gathering will unravel important results concerning the mechanisms and treatment of Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, Stroke, Autism, Migraine and other neurological disorders.

The meeting will be highlighted with some of the top influential personalities involved in solving the mysteries of different neurological disorders. The series of talks, poster presentations, workshops, discussions and networking events will keep participants engaged in learning and making new connections at NDS-2016.
Internet address

Fingerprint

Genomics
Proteomics
Alzheimer Disease
Biomarkers
Chronic Disease
Magnesium
Cerebrospinal Fluid
Premature Aging
Patents
Body Fluids
Proteome
Disease Progression
Early Diagnosis
Urine
Lipids
Health
Brain
Proteins

Cite this

Martins, I. (2016). The Role of Clinical Proteomics, Lipidomics and Genomics in the diagnosis of Alzheimer's Disease. Abstract from 2nd Neurological Disorders Summit , Baltimore, United States.
Martins, Ian. / The Role of Clinical Proteomics, Lipidomics and Genomics in the diagnosis of Alzheimer's Disease. Abstract from 2nd Neurological Disorders Summit , Baltimore, United States.
@conference{a56ea0d1518e4b7983e0cf9999331d9a,
title = "The Role of Clinical Proteomics, Lipidomics and Genomics in the diagnosis of Alzheimer's Disease",
abstract = "The early diagnosis of Alzheimer’s disease (AD) has become important to the reversal and treatment of neurodegeneration that may be relevant to premature brain aging that is associated with chronic disease progression. Clinical proteomics allows the detection of various proteins in fluids such as the urine, plasma and cerebrospinal fluid for the diagnosis of AD. Interests in lipidomics has accelerated with plasma testing for various lipid biomarkers that may with clinical proteomics provide a more reproducible diagnosis. The combination of proteomics with lipidomics may decrease the biological variability between studies and provide reproducible results that detect a community’s susceptibility to AD (Ref1). The diagnosis of chronic disease associated with AD that now involves genomics may provide increased sensitivity to avoid inadvertent errors related to plasma versus cerebrospinal fluid testing by proteomics and lipidomics that identify new disease biomarkers in body fluids, cells and tissues. The diagnosis of AD by various plasma biomarkers with clinical proteomics may now require the involvement of lipidomics and genomics to provide interpretation of proteomic results from various laboratories around the world. Technological advances allow novel biomarkers to be identified for the diagnosis of neurodisorders but novel patents may not be relevant to diagnostic discovery with relevance to autonomous disease that involves magnesium and its association with various chronic diseases (Ref2). Ref1. The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer’s Disease. Proteomes, 2016. ONLINE Ref2. Magnesium Therapy Prevents Senescence with the Reversal of Diabetes and Alzheimer’s Disease. Health, 2016.ONLINE",
author = "Ian Martins",
year = "2016",
month = "9",
day = "7",
language = "English",
note = "2nd Neurological Disorders Summit , NDS 2016 ; Conference date: 07-09-2016 Through 09-09-2016",
url = "https://neurodisordersconference.com/neurology-2016/",

}

Martins, I 2016, 'The Role of Clinical Proteomics, Lipidomics and Genomics in the diagnosis of Alzheimer's Disease' 2nd Neurological Disorders Summit , Baltimore, United States, 7/09/16 - 9/09/16, .

The Role of Clinical Proteomics, Lipidomics and Genomics in the diagnosis of Alzheimer's Disease. / Martins, Ian.

2016. Abstract from 2nd Neurological Disorders Summit , Baltimore, United States.

Research output: Contribution to conferenceAbstract

TY - CONF

T1 - The Role of Clinical Proteomics, Lipidomics and Genomics in the diagnosis of Alzheimer's Disease

AU - Martins, Ian

PY - 2016/9/7

Y1 - 2016/9/7

N2 - The early diagnosis of Alzheimer’s disease (AD) has become important to the reversal and treatment of neurodegeneration that may be relevant to premature brain aging that is associated with chronic disease progression. Clinical proteomics allows the detection of various proteins in fluids such as the urine, plasma and cerebrospinal fluid for the diagnosis of AD. Interests in lipidomics has accelerated with plasma testing for various lipid biomarkers that may with clinical proteomics provide a more reproducible diagnosis. The combination of proteomics with lipidomics may decrease the biological variability between studies and provide reproducible results that detect a community’s susceptibility to AD (Ref1). The diagnosis of chronic disease associated with AD that now involves genomics may provide increased sensitivity to avoid inadvertent errors related to plasma versus cerebrospinal fluid testing by proteomics and lipidomics that identify new disease biomarkers in body fluids, cells and tissues. The diagnosis of AD by various plasma biomarkers with clinical proteomics may now require the involvement of lipidomics and genomics to provide interpretation of proteomic results from various laboratories around the world. Technological advances allow novel biomarkers to be identified for the diagnosis of neurodisorders but novel patents may not be relevant to diagnostic discovery with relevance to autonomous disease that involves magnesium and its association with various chronic diseases (Ref2). Ref1. The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer’s Disease. Proteomes, 2016. ONLINE Ref2. Magnesium Therapy Prevents Senescence with the Reversal of Diabetes and Alzheimer’s Disease. Health, 2016.ONLINE

AB - The early diagnosis of Alzheimer’s disease (AD) has become important to the reversal and treatment of neurodegeneration that may be relevant to premature brain aging that is associated with chronic disease progression. Clinical proteomics allows the detection of various proteins in fluids such as the urine, plasma and cerebrospinal fluid for the diagnosis of AD. Interests in lipidomics has accelerated with plasma testing for various lipid biomarkers that may with clinical proteomics provide a more reproducible diagnosis. The combination of proteomics with lipidomics may decrease the biological variability between studies and provide reproducible results that detect a community’s susceptibility to AD (Ref1). The diagnosis of chronic disease associated with AD that now involves genomics may provide increased sensitivity to avoid inadvertent errors related to plasma versus cerebrospinal fluid testing by proteomics and lipidomics that identify new disease biomarkers in body fluids, cells and tissues. The diagnosis of AD by various plasma biomarkers with clinical proteomics may now require the involvement of lipidomics and genomics to provide interpretation of proteomic results from various laboratories around the world. Technological advances allow novel biomarkers to be identified for the diagnosis of neurodisorders but novel patents may not be relevant to diagnostic discovery with relevance to autonomous disease that involves magnesium and its association with various chronic diseases (Ref2). Ref1. The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer’s Disease. Proteomes, 2016. ONLINE Ref2. Magnesium Therapy Prevents Senescence with the Reversal of Diabetes and Alzheimer’s Disease. Health, 2016.ONLINE

M3 - Abstract

ER -

Martins I. The Role of Clinical Proteomics, Lipidomics and Genomics in the diagnosis of Alzheimer's Disease. 2016. Abstract from 2nd Neurological Disorders Summit , Baltimore, United States.